Feasibility and safety of radical prostatectomy for oligo- metastatic prostate cancer: theTesting Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial

Efficiency and safety of Thalidomide in combination with ADT and Docetaxel

TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment in Patients with mCRPC,

- Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study

Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX601) in patients with metastatic castration-resistant prostate cancer (mCRPC). (poster 140)

177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP

NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

Panel Discussion

Expert Comment